APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis
FRA:APPH • DE000A3CMGM5
11 EUR
0 (0%)
Last: Nov 14, 2025, 07:00 PM
Overall APPH gets a fundamental rating of 5 out of 10. We evaluated APPH against 52 industry peers in the Pharmaceuticals industry. APPH has a great financial health rating, but its profitability evaluates not so good. APPH has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- APPH had positive earnings in the past year.
- APPH had a negative operating cash flow in the past year.
- In multiple years APPH reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.70%, APPH is doing worse than 60.71% of the companies in the same industry.
- APPH's Return On Equity of 2.34% is on the low side compared to the rest of the industry. APPH is outperformed by 60.71% of its industry peers.
- APPH's Return On Invested Capital of 2.01% is on the low side compared to the rest of the industry. APPH is outperformed by 64.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.7% | ||
| ROE | 2.34% | ||
| ROIC | 2.01% |
ROA(3y)-4.37%
ROA(5y)-3.69%
ROE(3y)-9.26%
ROE(5y)-12.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- APPH has a Profit Margin (1.55%) which is comparable to the rest of the industry.
- APPH's Operating Margin of 2.60% is on the low side compared to the rest of the industry. APPH is outperformed by 64.29% of its industry peers.
- APPH's Operating Margin has declined in the last couple of years.
- APPH has a Gross Margin of 57.16%. This is in the lower half of the industry: APPH underperforms 67.86% of its industry peers.
- In the last couple of years the Gross Margin of APPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.6% | ||
| PM (TTM) | 1.55% | ||
| GM | 57.16% |
OM growth 3Y-32.83%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
2. Health
2.1 Basic Checks
- APPH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, APPH has about the same amount of shares outstanding.
- The number of shares outstanding for APPH has been reduced compared to 5 years ago.
- APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 6.01 indicates that APPH is not in any danger for bankruptcy at the moment.
- APPH has a Altman-Z score of 6.01. This is amongst the best in the industry. APPH outperforms 87.50% of its industry peers.
- APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.01 |
ROIC/WACC0.28
WACC7.19%
2.3 Liquidity
- APPH has a Current Ratio of 6.82. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
- APPH has a Current ratio of 6.82. This is amongst the best in the industry. APPH outperforms 98.21% of its industry peers.
- APPH has a Quick Ratio of 4.86. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
- APPH has a better Quick ratio (4.86) than 98.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.82 | ||
| Quick Ratio | 4.86 |
3. Growth
3.1 Past
- APPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.98%, which is quite impressive.
- The Revenue has grown by 31.12% in the past year. This is a very strong growth!
- The Revenue has been growing slightly by 3.89% on average over the past years.
EPS 1Y (TTM)106.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
3.2 Future
- Based on estimates for the next years, APPH will show a very strong growth in Earnings Per Share. The EPS will grow by 128.83% on average per year.
- The Revenue is expected to grow by 15.31% on average over the next years. This is quite good.
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 122.22, the valuation of APPH can be described as expensive.
- Based on the Price/Earnings ratio, APPH is valued a bit more expensive than the industry average as 67.86% of the companies are valued more cheaply.
- APPH's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.64.
- A Price/Forward Earnings ratio of 11.20 indicates a reasonable valuation of APPH.
- APPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. APPH is cheaper than 75.00% of the companies in the same industry.
- APPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.75, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 122.22 | ||
| Fwd PE | 11.2 |
4.2 Price Multiples
- APPH's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. APPH is more expensive than 69.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 30.66 |
4.3 Compensation for Growth
- APPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- APPH's earnings are expected to grow with 128.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y194.54%
EPS Next 3Y128.83%
5. Dividend
5.1 Amount
- APPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:APPH (11/14/2025, 7:00:00 PM)
11
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)N/A N/A
Inst Owners38.49%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap93.50M
Revenue(TTM)48.47M
Net Income(TTM)750.00K
Analysts82.86
Price Target13.77 (25.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)71.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 122.22 | ||
| Fwd PE | 11.2 | ||
| P/S | 1.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.92 | ||
| P/tB | 7.19 | ||
| EV/EBITDA | 30.66 |
EPS(TTM)0.09
EY0.82%
EPS(NY)0.98
Fwd EY8.93%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS5.7
BVpS3.76
TBVpS1.53
PEG (NY)0.31
PEG (5Y)N/A
Graham Number2.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.7% | ||
| ROE | 2.34% | ||
| ROCE | 3.08% | ||
| ROIC | 2.01% | ||
| ROICexc | 2.01% | ||
| ROICexgc | 3.75% | ||
| OM | 2.6% | ||
| PM (TTM) | 1.55% | ||
| GM | 57.16% | ||
| FCFM | N/A |
ROA(3y)-4.37%
ROA(5y)-3.69%
ROE(3y)-9.26%
ROE(5y)-12.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.09%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.79%
ROICexc growth 5YN/A
OM growth 3Y-32.83%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 214.53% | ||
| Cap/Sales | 7.92% | ||
| Interest Coverage | 9.69 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.82 | ||
| Quick Ratio | 4.86 | ||
| Altman-Z | 6.01 |
F-Score5
WACC7.19%
ROIC/WACC0.28
Cap/Depr(3y)153.48%
Cap/Depr(5y)119.91%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
EBIT growth 1Y113.36%
EBIT growth 3Y-34.04%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y16.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.68%
OCF growth 3YN/A
OCF growth 5YN/A
APONTIS PHARMA AG / APPH.DE FAQ
Can you provide the ChartMill fundamental rating for APONTIS PHARMA AG?
ChartMill assigns a fundamental rating of 5 / 10 to APPH.DE.
Can you provide the valuation status for APONTIS PHARMA AG?
ChartMill assigns a valuation rating of 4 / 10 to APONTIS PHARMA AG (APPH.DE). This can be considered as Fairly Valued.
What is the profitability of APPH stock?
APONTIS PHARMA AG (APPH.DE) has a profitability rating of 1 / 10.
What is the expected EPS growth for APONTIS PHARMA AG (APPH.DE) stock?
The Earnings per Share (EPS) of APONTIS PHARMA AG (APPH.DE) is expected to grow by 393.69% in the next year.